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Abstract
Background: Diffusion weighted magnetic resonance imaging (DW-MRI) holds great potential for monitoring
treatment response in cancer patients shortly after initiation of radiotherapy. It is hypothesized that a decrease in
cellular density of irradiated cancerous tissue will lead to an increase in quantitative apparent diffusion coefficient
(ADC) values. DW-MRI can therefore serve as a non-invasive marker of cell death and apoptosis in response to
treatment. In the present study, we aimed to investigate the applicability of DW-MRI in preclinical models to
monitor radiation-induced treatment response. In addition, we compared DW-MRI with ex vivo measures of cell
density, cell death and apoptosis.
Methods: DW-MRI was tested in two different syngeneic mouse models, a colorectal cancer (CT26) and a breast cancer
(4 T1). ADC values were compared with quantitative determinations of apoptosis and cell death by flow cytometry.
Furthermore, ADC-values were also compared to histological measurement of cell density on tumor sections.
Results: We found a significant correlation between ADC-values and apoptotic state in the CT26 model (P = 0.0031). A
strong correlation between the two measurements of ADC-value and apoptotic state was found in both models, which
were also present when comparing ADC-values to cell densities.
Conclusions: Our findings demonstrate that DW-MRI can be used for non-invasive monitoring of radiation-induced
changes in cell state during cancer therapy. ADC values reflect ex vivo cell density and correlates well with apoptotic
state, and can hereby be described as a marker for the cell state after therapy and used as a non-invasive response
marker.
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Background
Monitoring of treatment response in cancer patients is
of huge clinical importance to optimize therapeutic in-
terventions, and the general approach based on morph-
ology is described by the RECIST guidelines which were
last updated in 2009 [1]. However, non-invasive mea-
sures of functional changes in the tumor, e.g. induction
of cell death and cell density, may be of complementary
value for response monitoring.
One such potential imaging modality is diffusion
weighted magnetic resonance imaging (DW-MRI). Ini-
tially, this technique was focused on neuroimaging due
to the limited motion in the brain and hereby a de-
creased number of pitfalls and artifact shortcomings [2].
However, an increased methodical knowledge and less
hardware limitations has led to the use of DW-MRI in
most parts of the body [3].
DW-MRI is based on the brownian motion within
tissues, and molecule-movement being restricted by
cellular structures in high-density tissue e.g. solid
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cancers [4–6]. In more detail, DW-MRI measures the
indirect value of cellularity by applying the same gra-
dient at continuous short time intervals. The move-
ment of water molecules causes loss of signal through
spin dephasing, and an apparent diffusion coefficient
(ADC) value can be defined from the signal loss over
time [7, 8]. A high ADC-value hereby represents a
steep slope of signal loss and vice versa. It has been
shown that there is an inverse correlation between
cellular density and ADC, describing a high cellular
density as a low ADC-value due to high restriction in
tissue and hereby decreased water movement [9–11].
DW-MRI is described as a promising way to non-
invasively monitor treatment response shortly after
treatment initiation. Several clinical and preclinical stud-
ies are currently ongoing or published on the use DW-
MRI as a prognostic marker in various cancers [3, 6, 9,
12–18]. Accordingly, it has been shown that in general
there is an increase in ADC-value following effective
treatment. However, although the majority of studies
find an increase in ADC-value following therapy and a
correlation with long term survival or disease progres-
sion, contradictory and conflicting results have also been
reported [19, 20]. Furthermore, recommendations for
the use of DW-MRI was discussed in 2008 during “The
International Society for Magnetic Resonance in Medi-
cine Meeting” held in Toronto. Concerns for the lack of
understanding DW-MRI at a microscopic level was
among the points to be summarized in the meeting re-
port [21].
The aim of this study was therefore to evaluate the
feasibility of DW-MRI treatment response monitoring of
external radiotherapy and to evaluate how DW-MRI cor-
relates with changes in cell density and induction of
apoptosis in a preclinical setting to obtain knowledge of
the robustness of the method for translational purposes.
To do so, we studied the correlation between the non-
invasively collected ADC-values in tumors before and
after irradiation and ex vivo measures of cell density and
cell apoptosis by immunohistochemistry and flow cy-
tometry in two different murine models.
Methods
Tumor model
All experimental procedures were approved by the Da-
nish Animal Welfare Council, the Danish Ministry of
Justice (license no. 2016-15-0201-00920). Mice were
housed in IVC rack in Type III SPF cages with a max-
imum of 8 mice in each cage. Food and water was avail-
able ad libitum at all times.
Tumors were grown on female BalbC mice (Charles
River, Scanbur A/S, Karlslunde, Denmark) and mice were
included at 8 weeks of age after 1 week of acclimatization.
Mice were injected subcutaneously with either 3 × 105
CT26 WT (murine colon carcinoma, CRL-2638, ATCC,
Virginia, USA) cells or 5 × 105 4 T1 (murine stage IV
breast cancer cells, CRL-2539, ATCC, Virginia, USA) in a
total volume of 100 μL RPMI serum-free medium on the
lower part of the right flank. Roswell Park Memorial Insti-
tute (RPMI) medium supplemented with 10% Fetal Calf
Serum (FCS) and 1% penicillin-streptomycin (Biowest,
Nuaillé, France) was used for growth of both cell lines
prior to inoculation. In vitro growth of cells upon inocula-
tion were maintained in culture flasks (5% CO2 at 37
0 C).
During inoculation mice were anaesthetized with 3.5%
sevoflurane (Abbvie Inc., North Chicago, IL, USA) in a
mixture of oxygen and air (35% O2 and 65% N2). Tumor
size and body weight were measured continuously from
day 5 after implant to follow the development of tumors
and monitor health of the mice. Tumor size were calcu-
lated from the formula of 0.52 · (W2 · L), where L repre-
sents the length and W for the width measured by
external caliper. When tumors reached a mean size of ap-
proximately 170mm3, mice were randomized into three
different groups of six mice for both models. Groups in-
cluded an untreated control group and two treatment
groups receiving either 10Gy or 15Gy of radiation ther-
apy. Motivations for treatment doses were chosen based
on the known sensitivity of the included tumor models to-
wards radiation therapy to investigate doses inducing a
treatment response, but without diminishing investigated
tumors completely during study time in order to sustain
tumor tissue for sampling at day 4. Filatenkov and col-
leagues have shown how 30Gy leads to complete remis-
sion in CT26 tumors and the doses were set based on this
and studies within our own department showing treat-
ment responses from doses of 10 and 15Gy in both
models [22]. Radiation therapy was delivered at 1 Gy/min
(320 kV/12.5mA) using a biological irradiator X-Rad 320
(PXI Precision X-ray, North Branford, Connecticut, USA).
MRI protocol
DW-MRI scans were performed using a Preclinical BioS-
pec MR 7 T Scanner (Bruker, Ettlingen, Germany) and a
20mm planar RF surface coil. Both an anatomical T2-
weighted sequence and diffusion-weighted sequence was
acquired. The T2-weighted anatomical sequence was
performed using the following parameters; TR/TE. 2500/
35 milliseconds, image size: 256 × 256, Field of view
(FOV): 30 × 30 mm, averages: 2, slice thickness: 0.7 mm,
and scan time 2min 40 s. Diffusion-weighted EPI scan
sequence was performed using the following parameters;
TR/TE: 550/24 milliseconds, image size: 96 × 96, FOV:
30 × 30 mm, averages: 6, segments: 6, slice thickness: 0.7
mm, b-values: 0, 100, 200, 600, 1000, 1500, 2000, and
scan time 2min 18 s. An extended shimming procedure
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and B0-map was included in diffusion-weighted protocol
to decrease artifacts and noise in images.
All mice had MRI performed at baseline before radi-
ation therapy and daily for 4 days following irradiation
to monitor treatment response. Mice were anesthetized
as previously described, placed on a water-heated bed to
stabilize body temperature, and respiration was moni-
tored during entire scan procedure.
Image analysis was performed in ParaVision 6.0.1 soft-
ware (Bruker, Ettlingen, Germany). Region of interests
(ROI) were drawn over tumor tissue in a circular shape
on a single axial slice placed to cover center of tumor in
a maximum volume. Tissue ADC-values were calculated
using bi-exponential signal intensity plot fitting, and re-
sults accordingly describe the mean ADC-value in a cen-
tral slice of the tumor.
Apoptosis quantification by Annexin V
After MRI scan on day four after radiation therapy, all
mice were euthanized by cervical dislocation and tumors
collected for ex vivo analysis. Tumors were harvested
and stored in MACS tissue storage solution until disso-
ciated with Tumor Dissociation kit (Miltenyi Biotec,
Germany) using a gentleMACS™ Octo Dissociator (Mil-
tenyi Biotec, Germany). Dissociation was performed fol-
lowing the manufacturer’s standard protocol. Cells were
washed and diluted into single cell suspensions before
assay detection, and red blood cells lysed using Versa-
Lyse™ Lysing Solution, according to manufacturer’s
protocol (Beckman Coulter, Brea, Californien, USA). De-
tection of apoptotic cells, apoptotic stage, and dead cells
in tumor tissue was obtained using MUSE® Cell Analyzer
and accompanying Annexin V & Dead Cell Kit (Merck
Millipore, Darmstadt, Germany) [23].
Results of the cellular counts are given in percentages
of the gated cells and in number of total cells counted in
the gated area. Gates were set in a default setting on a
test sample of tissue, and kept fixed for all samples in
data set. Results are presented as percentage of all apop-
totic cells, including both cells gated as early apoptotic
and late apoptotic.
Immunohistochemistry protocol
Immunohistochemistry (IHC) was performed on formalin-
fixed, paraffin-embedded 4 μm tumor sections that were
stained with haematoxylin and eosin for 5 and 3min, re-
spectively. Separate groups of mice were included for this
study. A total of 4 mice were included for each treatment
group in the two different models of either CT26 or 4 T1.
Subsequently slides were mounted for electronic slide scan-
ning (Axio scan, Carl Zeiss, Germany) (pixel size 0.022 ×
0.022 μm). Five regions of interests were used to generate a
reflection of the full slide environment. Cellular density was
determined using the “color deconvolution”-function in Fiji
[24] to isolate the haematoxylin-stain image. The isolated
haematoxylin stained image was extracted to binary values
and the nuclei density was determined by excluding frag-
ments and artifacts by automated exclusion of structures
below a cut-off size of 50 pixels2. All structures above 50
pixels2 were hereby counted as cellular nuclei, and the
“watershed”-function was used to differentiate if stacks of
nuclei were seen, and hereby counted as individual nuclei.
Five density values are thereby included for each tumor
slide, and two individual slides for each tumor was
evaluated.
Statistical analysis
Statistical analysis was performed in GraphPad 7
(GraphPad Software, San Diego, CA, USA). Results of
tumor volumes are presented as mean ± SEM (Standard
Error of Mean). Analysis of data from tumor growth,
ADC-values, histological staining, and apoptotic assay
was performed using one-way ANOVA variance analysis
to evaluate differences over time or between treatment
groups. Pearson correlation analysis was used to evaluate
correlations between data sets. P-value <0.05 was con-
sidered statistically significant in all cases.
Results
DW-MRI scan sequence was performed with high quali-
tative reproducibility and limited artifacts. Optimal
image quality seen in center of coil, but no eddy cur-
rents- or motion artifacts were seen in either of the
slices, which is otherwise known to be an obstacle for
EPI sequences.
Tumor growth for all groups in both models are
shown in Fig. 1a and b as mean ± SEM in each group.
Successful tumor inhibition was seen in all treatment
groups for both models over time given by a significant
increase in control groups, which was absent in all treat-
ment groups. The average non-treated CT26 tumor size
(± SEM) increased 240% from 170 ± 47 mm3 to 400 ±
110 mm3 from day 0 to day 4. In the group treated with
10 Gy, a decrease in size of 7% from 170 ± 35 mm3 to
160 ± 48 mm3 was observed, and in the 15 Gy treated
group a decrease of 9% in size from 170 ± 28mm3 to
155 ± 29 mm3. The tumor size at day 4 of the treated
groups were approximately 60% lower than in the un-
treated group (one-way ANOVA, P = 0.0416). Non-
treated 4 T1 tumors increased 210% in group mean size
(± SEM) from 160 ± 12 mm3 to 335 ± 18 mm3 from day
0 to day 4. In the group treated with 10 Gy, a mean
tumor size decrease of 4% from 160 ± 7mm3 to 153 ±
13mm3 was observed, and in the 15 Gy treated group a
tumor size decrease of 19% from 160 ± 11 mm3 to 130 ±
10mm3 was observed. The size at day 4 of the treated
groups were approximately 55% lower for the 10 Gy
group and 60% lower for the 15 Gy group, than in the
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untreated group (one-way ANOVA, P = 0.0001). Suc-
cessful tumor inhibition is seen in all treatment groups
for both models over time given by a significant increase
in tumor size for the control groups, which is absent in
all treatment groups (significance levels shown in Fig. 1a
and b). Larger variations in tumor size were seen for the
syngeneic CT26 colon cancer model compared to the
syngeneic 4 T1 breast cancer model, which is also
depicted by the p-values for comparison on day 4.
ADC-values on the DW-MRI scans made on day 0, 1,
2, 3, and 4 increased for treatment groups compared to
control group for both models (Fig. 1c and d). ADC-
values were defined as the mean value for the center of
tumor volume, detected as a circle-shaped ROI to in-
clude as much tumor as possible in the chosen slice.
ADC results are presented in relative values to describe
the systematical changes in tissue after treatment. There
was a mean increase of between 15 to 20% for the two
treatment groups in the CT26 model compared to a
mean decrease of approximately 2–5% in the control
group at day 3 (one-way ANOVA, P = 0.0190). Equiva-
lent pattern is seen for the 4 T1 model, where a mean
increase of approximately 10% in ADC-value for the two
treatment groups are seen compared to a 10% decrease
in ADC-value for the control group at day 3 (one-way
ANOVA, P = 0.0014).
Representative examples of MR scans (T2-weighted
anatomical scan, DWI and ADC-map) from each group
in both models are shown in Fig. 2.
Percentages of apoptotic cells determined by ex vivo
analysis using Annexin V staining are presented in Fig. 3a
and b. Here, a significant increase in apoptotic cell per-
centages of tumors after treatment compared to un-
treated tumors was observed in the CT26 model (one-
way ANOVA, p = 0.0077), presented by an increased
apoptotic cell proportion changing from a mean of 35 ±
1% in the control group to a mean of 45 ± 3% in the two
treatment groups. Contrarily, no significant differences
were found in the 4 T1 model although a similar ten-
dency was apparent, and an increase in apoptotic cell
percentages was observed ranging from a mean percent-
age of 37 ± 2% in the control group to an increase of
45 ± 4% in both treatment groups. Lack of significance is
most likely due to increase in variance in the control
group for the apoptotic results of the 4 T1 model com-
pared to the CT26 model.
Fig. 1 Tumor volumes (mm3) calculated from external caliper measurements for tumor-bearing mice of both CT26 (a) and 4 T1 model (b).
Volumes are described by mean ± SEM (n = 6 mice/group). Irradiation was performed on Day 0. Bottom row presents systematic ADC-results over
time in percent compared to baseline (mean ± SEM) for CT26 (c) and 4 T1 tumors (d), respectively. ADC-values are extracted from MRI scans in
ROI volume including central part of tumor. *) p < 0.05; **) p < 0.01, ***) p < 0.001: represents the systematic changes in tumor size for each group
over time (one-way ANOVA calculations on repeated measurements), and the #) p < 0.05; ##) p < 0.01, ###) p < 0.001 represents differentiation
between groups from one-way ANOVA at marked day in figure, e.g. tumor size at Day 4 comparison
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Figure 3c and d illustrates the ADC-values at day 4
for individual tumors compared to the percentage of
apoptotic cells from the same tumor. A strong signifi-
cant positive correlation was found between ADC-
values of tumors and corresponding percentage of
apoptotic cells for both the CT26 tumors (Pearson
r = 0.657, P = 0.0031) and the 4 T1 tumors (Pearson
r = 0.508, P = 0.031).
For IHC analysis, additional tumors were collected 4
days after identical radiation treatment and the direct
tumor cell-densities were measured by nuclei-staining
and counting. Results of tumor-cell nuclei-staining in
both tumor models are shown in Fig. 4a and b. Figure 4c
illustrate a representative IHC section and an image of
the quantification of cell nuclei. From these analyses, a
significant decrease in cellular density after radiation
Fig. 2 MRI images shown for both anatomical T2-weighted scan, DWI scan from shortest b-value, and overlay of anatomical image and ADC-
map. Depicted is one mouse from each group in both models. The T2-weighted anatomical sequence was performed on Bruker 7 T preclinical
MRI system using the following parameters; TR/TE. 2500/35 milliseconds, image size: 256 × 256, Field of view (FOV): 30 × 30 mm, averages: 2, slice
thickness: 0.7 mm, and scan time 2 min 40 s. Diffusion-weighted scan sequence was performed using the following parameters; TR/TE: 550/24
milliseconds, image size: 96 × 96, FOV: 30 × 30 mm, averages: 6, segments: 6, slice thickness: 0.7 mm, b-values: 0, 100, 200, 600, 1000, 1500, 2000,
and scan time 2min 18 s
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treatment is observed compared to untreated controls in
both cases (one-way ANOVA, P < 0.0001). For the CT26
model a mean group decrease from 2250 ± 18 nuclei per
ROI in the control group to 1920 ± 22 nuclei per ROI
for the 10 Gy treatment group, and a further mean de-
crease to 1860 ± 25 nuclei per ROI in the 15 Gy treat-
ment group. Similarly for the 4 T1 model, mean nuclei
count per ROI in the control group was 2000 ± 45, and a
decrease in group mean for the 10 Gy treatment group
results in count of 1800 ± 35 nuclei per ROI compared
to a mean of 1660 ± 44 nuclei per ROI for the 15 Gy
treatment group.
Discussion
DW-MRI scans may provide a method of non-invasive
measurement of therapeutic efficacy. This is based on
the hypothesis that DW-MRI describes an indirect state
of cell density in tumor tissue where a lowering in cell
density equals an increase in ADC-value [5]. Cell dens-
ity, size, macromolecules, and myelin layers are among
structures that restrict the water movements, which is
basis for the proposed hypothesis of using DWI-MRI.
DW-MRI is currently being tested in both preclinical
and clinical studies [5, 11, 15–17, 25].
In the current study, we found that radiation treatment
of tumors increases ADC-values following the induction
of cellular damage and apoptosis in the irradiated region,
which is in accordance with Baskar et al., stating that
apoptosis is one of two main factors leading to cell deatch
after irradiation [26]. The validity of the ADC-value as an
indirect measure of cellular density was investigated by
comparing with ex vivo measurement of cellular density.
The ex vivo quantification of cellular density is a direct
measurement, and introduces the need for a biopsy of tis-
sue in a clinical setting and is therefore heavily influenced
by micro regional differences, e.g. necrotic or hypoxic re-
gions, and thereby sampling error in clinical patients.
DW-MRI scans on the other hand can cover larger re-
gions and produce an overall quantitative measurement of
important tumor characteristics using a non-invasive and
repeatable method. This is very important as clinical tu-
mors are highly heterogeneous in terms of tumor micro-
environment and response. To optimally perform the
comparisons, tumor tissues for post-mortem analysis were
Fig. 3 Results of apoptotic cell percentages for tumor-bearing mice of both CT26 (a) and 4 T1 (b). Results obtained using MUSE® Cell Analyzer
and apoptotic cell percentages are described as mean ± SEM in the three treatment groups including six mice each on Day 4 after treatment.
Statistical significance was found using one-way ANOVA testing with p-value of 0.0077 for CT26 model, but no significance found for 4 T1 model.
Bottom row presents correlation of ADC-results at Day 4 and apoptotic cell percentages on the same day for CT26 (c) and 4 T1 (d), respectively.
ADC-values are extracted from MRI scans in ROI volume including central part of tumor, and here presented in original values at Day 4.
Correlation analysis was made using Pearson correlation, resulting in values of r = 0.657 and p = 0.0031 for the CT26 tumors, and r = 0.508, p =
0.0319 for the 4 T1 tumors
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harvested in an un-paired setting, but with identical treat-
ment groups of both included models. Compatible results
were found between ex vivo cellular density and ADC
values, validating DW-MRI as a non-invasive method for
cellular density measurement. Given the high predictabil-
ity and reproducibility in the two investigated models, it
was assumed that tissue state in an un-paired setting cor-
responds to the tumor samples used for the paired correl-
ation between DW-MRI and apoptotic cell percentages.
However, the limitation of no fingerprint comparison be-
tween cellular densities and ADC-values needs to be
stated when reviewing the results.
The apoptotic cell percentages found in study showed
an increase for all treatment groups, but also a rather high
percentage in the control groups (approx. 35% apoptotic
cells). The level of apoptosis in the control groups could
be present due to necrotic regions occurring as a result of
increasing tumor size, compared to treated tumors, lead-
ing to outgrowth of capacity for neovascularization and
formation of hypoxic areas. The heterogeneous structure
of the included models is more compatible to clinical tu-
mors, and an advantage of the syngeneic tumor model
making them highly resemble to the clinical situation [27,
28]. However, one limitation to be emphasized is that the
DW-MRI data origins from on single slice in tumor
whereas the apoptotic cell percentages are calculated from
whole tumor volume. Spatial correlation between the two
parameters are hereby precluded, which could affect the
obtained results.
Despite these observations, the DW-MRI method does
seem to possess some degree of uncertainty given that
the results are highly sensitive and thereby susceptible to
heterogeneity in tumor tissue as described above. This
may explain the conflicting reporting’s in published
Fig. 4 Nuclei count for tumor-bearing mice of both CT26 (a) and 4 T1 (b) (mean ± SEM, n = 8 slides/group). Statistical significance is found using
one-way ANOVA testing (p < 0.0001 for both models). * depicting statistical differences of multiple comparisons compared to control group.
Bottom row (c) presents examples from HE staining with paired deconvoluted binary images to show the nuclei count in the two models for all
groups. Nuclei counts are calculated as number of nuclei per ROI area from five different ROIs in tumor slide in all groups. The depicted binary
images are only for visualization and not does not resemble the ROI used for data analysis
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studies [29–31]. To use DW-MRI to determine patient
outcomes in a clinical setting, a standardized protocol
for result validation is mandatory [32]. Yet, this does not
exist. A proposed method could be to set a value of per-
cent increase in ADC-value normalized to baseline scan
to stratify responders from non-responders at a given
time after treatment initiation. Threshold value does,
however, need to account for method variance and tis-
sue heterogeneity. For the two different cancer models
investigated in our study, a cancer-type specific cellular
density was found. The CT26 tumors had higher nuclei
count density, and consequently lower ADC-values,
compared to the 4 T1 model (data presented in Fig. 3c
and d). In addition, the CT26 model seemed more sensi-
tive to irradiation and displayed a more rapid decrease
in cellular density and increase in ADC values compared
to the 4 T1 model.
A study similar to ours from Paevangelou et al. previ-
ously showed that ADC-value can be used as biomarker
for early treatment response to cytotoxic drugs [33].
This matches with data obtained in the present study
where ADC-values correlated to the cellular density, but
not consistently to level of apoptotic cells. In our study
the total level of apoptotic cells (including both early
and late apoptotic state) correlated to ADC-values. In
order for DW-MRI to be used as prognostic marker, re-
sults indicate that late cell-death and potentially changes
in tissue structure needs to be present at the time of im-
aging. The use of DW-MRI has been proposed as an in-
dividual marker for treatment response [34], but also as
a complementary marker to FDG-PET [35].The combin-
ation of the non-invasive evaluation of both cellular
density (ADC) and metabolic activity could be used to
better predict therapeutic outcome, but further clinical
studies are needed to verify this.
Studies in different types of cancer have also proposed
DW-MRI as a marker to distinguish benign and malig-
nant tumors and to evaluate the aggressiveness of cancer
based on ADC-values, but that goes beyond the scope of
the present study [36–40].
Conclusion
Our study found that DW-MRI may be used for re-
sponse monitoring in radiation therapy. ADC-values re-
flect both cellular density and apoptosis in the two
different tumor types investigated in our study.
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